AFONSO SANTINE MAGALHAES MESQUITA VELEZ

Ms. AFONSO SANTINE MAGALHAES MESQUITA VELEZ

UFRRJ
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GSGabriela Alves De Souza
Gabriela Alves De Souza
LCLorrane de Souza Chaves
Lorrane de Souza Chaves
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
JLJorge Lucas F. Lacerda
Jorge Lucas F. Lacerda
PPPaulo Pitasse-Santos
Paulo Pitasse-Santos
Marco Edilson Freire De LimaMarco Edilson Freire De Lima
Marco Edilson Freire De Lima
Background: Anticancer therapies represent the primary treatment option for a significant number of cancer patients globally; however, many of these treatments are associated with severe side effects as they target molecular structures present in both cancerous and healthy cells. In a similar context, the treatment of Chagas disease, a neglected tropical illness, is hindered by the high toxicity of the currently available drugs. Researchers are increasingly focusing on the development of safer and more selective alternatives, with natural compounds being studied as potential starting points for the creation of more effective drug candidates with a favorable therapeutic index. Objectives: The aim of this study was to design simplified curcumin-derived structures that preserved or enhanced their therapeutic activity against human lung cancer cell lines and T. cruzi, while also improving bioavailability and minimizing toxicity. Methods: In this study, curcumin and two natural curcuminoids inspired the synthesis of a chalcone and a set of bis-chalcones, compound classes known for their enhanced stability compared with their natural parent derivatives. The synthetic strategy used was the acid-catalyzed aldol condensation reaction. The stability profiles, IC50 values against A549 and H460 tumor cell lines, and trypanocidal activity against T. cruzi amastigotes of these derivatives were assessed. Results: The synthesized derivatives exhibited improved stability compared with the parent compounds, along with lower IC50 values in both A549 and H460 tumor cell lines. Additionally, one of the new analogs showed promising trypanocidal activity against T. cruzi amastigotes. Conclusions: This study provides a potential pathway toward the development of more effective and less toxic treatments for both cancer and Chagas disease. The simplified curcumin derivatives represent a promising foundation for designing new therapeutic agents with improved bioavailability and efficacy.

26 December 2025 in ACS Omega
Verified
Journal Article
Open access
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
OCOtávio Chaves
Otávio Chaves
Carlos SerpaCarlos Serpa
Carlos Serpa
FSFatma M. Salem
Fatma M. Salem
BLBibo Li
Bibo Li
Marco Edilson Freire De LimaMarco Edilson Freire De Lima
Marco Edilson Freire De Lima
Effective and safe treatments for neglected tropical diseases caused by parasites, such as Chagas disease and sleeping sickness, remain lacking, posing a significant challenge for researchers worldwide. The rational design of dimeric compounds inspired solely by the pharmacophoric core of benznidazole (2-nitroimidazole) has proven to be a promising strategy for antiparasitic development. Thus, in the present work, it was increased the linker between the active units (2-nitroimidazole) to improve the interaction with TcNTR, facilitating the bioactivation of the longest dimers. Biological assays confirmed this, demonstrating that all compounds were active against replicative intracellular amastigotes of Trypanosoma cruzi (Tulahuen C2C4-LacZ). Notably, longer-chain dimers exhibited remarkable potency (IC50 < 1.0 μM). These compounds also showed significant activity against T. b. brucei and demonstrated very low cytotoxicity in mammalian cells, highlighting their selectivity, especially among the longer-chain dimers. These findings support the development of dimeric 2-nitroimidazole derivatives as selective agents against trypanosomes.

28 September 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
ISIdalia Maria Ferreira dos Santos
Idalia Maria Ferreira dos Santos
ESElias Barbosa da Silva-Junior
Elias Barbosa da Silva-Junior
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
Leonardo Freire-de-LimaLeonardo Freire-de-Lima
Leonardo Freire-de-Lima
AMAlexandre Morrot
Alexandre Morrot
Debora Decote-RicardoDebora Decote-Ricardo
Debora Decote-Ricardo
Leishmania spp. are obligatory intracellular parasites that primarily infect macrophages. The macrophage immune response plays a pivotal role in determining the control or progression of infection. “M1-like” macrophages mediate parasite clearance through the production of nitric oxide, pro-inflammatory cytokines, and reactive oxygen species, whereas “M2-like” macrophages contribute to infection progression by exerting anti-inflammatory effects. The capsular polysaccharides Glucuronoxylomannan (GXM) and glucuronoxylomannogalactan (GXMGal) from Cryptococcus neoformans are capable of immunomodulating the macrophage response. GXM exhibits immunoregulatory activity, whereas GXMGal induces a pro-inflammatory response. Although the activity of these polysaccharides has been studied in cryptococcosis, their immunomodulatory potential in other infectious models remains largely unexplored. Here, we investigated the effects of GXM and GXMGal on Leishmania major infection in murine peritoneal macrophages. Murine peritoneal macrophages were infected with L. major and, 24 h post-infection, treated with 50 μg of either GXM or GXMGal. Our data revealed that GXM treatment enhanced L. major infection, while GXMGal treatment had no significant effect on the parasitic load in infected macrophages.

29 January 2026 in Chemistry
Verified
Journal Article
Open access
PDF file
TSThiago de Souza Dias Silva
Thiago de Souza Dias Silva
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
TRTIAGO RIBEIRO RODRIGUEZ
TIAGO RIBEIRO RODRIGUEZ
JSJoão Vitor Costa Silva
João Vitor Costa Silva
H-Henrique Previtalli -Silva
Henrique Previtalli -Silva
Marco Edilson Freire De LimaMarco Edilson Freire De Lima
Marco Edilson Freire De Lima
This work reports the synthesis and characterization of a new molecular hybrid 4, created by combining 1,4-naphthoquinone with the drug zidovudine (AZT) through an azide-alkyne cycloaddition reaction catalyzed by Cu1+. In vitro studies assessed the anti-trypanosomatid activity of hybrid 4, along with its precursors and synthetic intermediates (1, 2, and 3), against Trypanosoma cruzi (T. cruzi Tulahuen C2C4 LacZ), Trypanosoma brucei (T. b. brucei 427), and Leishmania infantum, as well as cytotoxicity in RAW 264.7 macrophages and LLC-MK2 cells. The biological results confirm the molecular design, showing that the new hybrid is effective against both epimastigotes and amastigotes of T. cruzi (IC50 = 22.26 ± 5.78 μM and 143.10 ± 5.79 μM, respectively), with approximately 4.5-fold better capacity than AZT to inhibit the epimastigote form. Additionally, the hybrid was also active against bloodstream T. b. brucei (IC50 = 54.47 ± 6.70 μM), with approximately 2.2-fold better capacity than AZT to inhibit this parasite. It also shows low toxicity in RAW 264.7 macrophages (CC50 > 200 μM) and LLC-MK2 cells (CC50 > 200 μM). For example, hybrid 4 exhibited approximately a 6.6-fold higher SI than 1,4-naphthoquinone 1 against T. cruzi amastigotes. In this context, the work contributes to the broader knowledge base guiding the design of hybrid molecules for antiparasitic chemotherapy. It provides a rational foundation for preparing subsequent, more potent analogues.

1 January 2022 in Química Nova
Verified
Journal Article
Closed access
DPDouglas Pinto
Douglas Pinto
GSGabriela de Souza
Gabriela de Souza
PPPaulo Pitasse-Santos
Paulo Pitasse-Santos
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
DDDebora Decote-Ricardo
Debora Decote-Ricardo
Marco Edilson Freire De LimaMarco Edilson Freire De Lima
Marco Edilson Freire De Lima
THE POTENTIAL OF NATURAL XANTHONE α-MANGOSTIN IN THE DEVELOPMENT OF NOVEL ANTIINFECTIVE AGENTS: A REVIEW. The mangosteen (Garcinia mangostana, Linn.) is a tropical fruit cultivated in the tropical forests of Southeast Asian countries. It is recognized as the queen of fruits due to its unique color, aroma, and flavor. It has been used for centuries in Southeastern Asian traditional medicine for the treatment of various diseases. Many functional molecules with high medicinal value are obtained from the pericarp of mangosteen fruit, whose major constituent is xanthone α-mangostin. Several studies have been carried out over the last decades to further investigate and understand the pharmacological properties associated with the plant and its main chemical constituents, belonging to the class of xanthones. In addition, numerous in vitro and in vivo studies related to mangosteen have been published, indicating its importance and its potential application in medicinal chemistry. Prenylated xanthones, which include α-mangostin, are secondary metabolites particularly common in plants belonging to the Clusiaceae family. These substances have been intensively investigated for their potential as biologically active agents. This article describes a critical analysis of published data related to the properties of α-mangostin, aiming to provide a more detailed view of its potential as a chemotherapeutic agent for the prevention and treatment of infectious diseases.

27 May 2025 in ACS Omega
Verified
Journal Article
Open access
RSRafael Ferreira dos Santos
Rafael Ferreira dos Santos
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
GSGabriel Fulgencio dos Santos
Gabriel Fulgencio dos Santos
PPPaulo Pitasse-Santos
Paulo Pitasse-Santos
BOBruno Sena de Oliveira
Bruno Sena de Oliveira
RCRosane Nora Castro
Rosane Nora Castro
Geopropolis is a natural antibiotic produced by stingless bees, supplemented with earth and clay. Bee products are a promising source of natural bioactive compounds with potential for the development of new drugs for neglected tropical diseases, such as Chagas disease. This study analyzed extracts of Melipona mondury geopropolis from the Bosque da Barra da Tijuca (RJ, Brazil) and evaluated their activity against Trypanosoma cruzi. The extracts were obtained using commercial grain alcohol 96° GL and fractionated with hexane and dichloromethane. The antichagasic activity was determined, with IC50 values ranging from 4.54 to 53.02 μg/mL. Phytochemical investigation of the dichloromethane fraction resulted in the isolation of two C-methylated flavanones, (2S)-strobopinin and (2S)-cryptostrobin, which were identified for the first time in Brazilian geopropolis. These compounds showed IC50 values of 21.21 μM and 21.55 μM, respectively, with distinct cytotoxities: 33.80 μM for strobopinin and 99.79 μM for cryptostrobin. Molecular modeling studies were conducted to propose a mechanism of action on a candidate enzyme target, glyceraldehyde-3-phosphate dehydrogenase, and possible reasons for the selectivity differences caused by C-methylation. The results highlight M. mondury geopropolis as a promising natural source of antiparasitic agents, supporting its potential for drug development.